bosentan anhydrous has been researched along with Diabetes Mellitus, Adult-Onset in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y | 1 |
| Alicic, RZ; Tuttle, KR | 1 |
| Hopman, MT; Schreuder, TH; Thijssen, DH; van Lotringen, JH | 1 |
| Duncker, DJ; Hopman, MT; Schreuder, TH; Thijssen, DH | 1 |
| Figulla, HR; Franz, M; Goebel, B; Jung, C; Lichtenauer, M; Pernow, J; Rafnsson, A; Wernly, B | 1 |
| Bengtsson, M; Kalani, M; Papadogeorgos, NO | 1 |
| Ergul, A; Kelly-Cobbs, AI; Portik-Dobos, V; Sachidanandam, K | 1 |
| Ergul, A; Li, W; Sachidanandam, K | 1 |
| Böhm, F; Brismar, K; Gonon, A; Pernow, J; Rafnsson, A; Settergren, M | 1 |
| Brismar, K; Jung, C; Pernow, J; Rafnsson, A | 1 |
2 review(s) available for bosentan anhydrous and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
6 trial(s) available for bosentan anhydrous and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Impact of endothelin blockade on acute exercise-induced changes in blood flow and endothelial function in type 2 diabetes mellitus.
Topics: Aged; Blood Flow Velocity; Bosentan; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Exercise; Hand Strength; Humans; Male; Middle Aged; Netherlands; Regional Blood Flow; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation | 2014 |
Randomized controlled trial using bosentan to enhance the impact of exercise training in subjects with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Homeostasis; Humans; Male; Middle Aged; Physical Conditioning, Human; Physical Fitness; Sulfonamides; Vasodilation | 2014 |
Effect of endothelin-1 and endothelin receptor blockade on the release of microparticles.
Topics: Bosentan; Cell-Derived Microparticles; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Middle Aged; Receptor, Endothelin A; Sulfonamides | 2016 |
Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes.
Topics: Aged; Angioplasty, Balloon, Coronary; Bosentan; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Endothelin A Receptor Antagonists; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Peptides, Cyclic; Receptor, Endothelin A; Stents; Sulfonamides; Treatment Outcome | 2009 |
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
Topics: Aged; Albuminuria; Antihypertensive Agents; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Microvessels; Middle Aged; Peripheral Vascular Diseases; Severity of Illness Index; Sulfonamides; Vasodilation | 2012 |
Endothelial progenitor cells in relation to endothelin-1 and endothelin receptor blockade: a randomized, controlled trial.
Topics: Aged; Albuminuria; Biomarkers; Bosentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Receptor, Endothelin A; Stem Cells; Sulfonamides | 2013 |
2 other study(ies) available for bosentan anhydrous and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes.
Topics: Animals; Blood Glucose; Body Weight; Bosentan; Collagen Type I; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; Mesenteric Arteries; Rats; Rats, Inbred Strains; Rats, Wistar; Sulfonamides; Tunica Media | 2010 |
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2011 |